In addition, recent advances such as HSP-targeting proteolysis-targeting chimeras (PROTACs), which enable the selective degradation of chaperone proteins[156,157], and nanomedicine-based delivery systems, which enhance bioavailability and tumor selectivity[158], represent promising strategies to address the limitations of earlier generations of inhibitors. This evidence concerns the gene HSP90B2P and neoplasm.